Member Info for Laura2022

Tyke and max

Thankyou

Youre most welcome North

Hello

I have just tried to look at companies where they are trading well below the standard sector average ( normally should be valued x 10 annual turnover/earnings)

Eg PYC at £1.3mln only valued x 1.5 wheras sector is x 10 to x30 )

Hope that helps

That's because...on top of other things...60%+ shares held by funds

1mln buy full ask seems to have taken the stock

[ ] Presentation notes Sept 2025

Key growth in all areas , particularly bio statistics, CEO very pleased and very confident about the niche growth markets many of which are now mandatory under EU law and most could well become mandatory for drug design. Positive regulatory environment eg FDA

[ ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[ ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Biostatistics 24% CAGR $40bln market

Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)

General overviews

Costs at just 3% therefore tracking or below inflation in 2025 so very tight cost mgmt

Total Income at 3yr high and bolstered by moving into new therapeutic areas such as immunology and cardiovascular

Just after year end received £250,000 + and will recieve £60k grant, therefore cash position as of July was almost £800,000

Have applied for other grants and will announce if/when progressed

Conversion rate 2022-2024 was 27%

Conversation rate 2025 jumped to 45%

6 late stage contracts due

The "right team" now finally assembled in all key growth areas

Excited for future

Peer comparisons

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year ( x 9)

PYC £1.4mln and £0.85mln full year ( x less than 2 )

IMM £60mln cap (pre revenue)

GENI (£10mln) revenues £1.6mln, losses £2.4

Tyke

I'm trying to buy but finding it difficult to get any real size

Great to see OBD

Well done

Hopefully PYC next

Post-period End

· New Phase III clinical trial protocol submitted to the FDA to support an expanded indication for XENOVIEW® (xenon Xe 129 hyperpolarised). The proposed expansion would include quantitative gas-exchange imaging in addition to the current FDA approved ventilation imaging indication, useful in the diagnosis of additional pulmonary diseases

· Polarean's Xenon MRI named a nominee for Best Medical Technology in the prestigious 2025 Prix Galien USA Awards. This recognition highlights our commitment to advancing pulmonary imaging and improving patient care. The Prix Galien USA is widely considered the "Nobel Prize of medical innovation," honouring products FDA-approved within the last five years that bring significant impact to human health

· Process initiated with Philips to approve the FDA-cleared XENOVIEW® Chest Coil for use on Philips 3T MRI systems, further strengthening the collaboration

· Polarean continued to build international momentum, with senior leadership engaging clinicians and partners in China to highlight the potential of the Xenon MRI platform to advance lung health. China is the world's largest MRI market, making it a strategically important region for future growth

As the pace of innovation accelerates, so too does the need for smarter, data-driven decisions in drug development.

This week, our Head of Business Development, Hayley Close, and Head of Biometrics, Jesse Thissen, are in Vienna for #BIOEurope – meeting with partners and innovators to discuss how our combined expertise in Model-Informed Drug Development (MIDD), Biostatistics, and Bioinformatics is helping to make that shift a reality.

🗨️ If you’re attending #BIOEurope, reach out via the Partnering System to connect with Hayley or Jesse and explore how data-driven solutions can accelerate your next milestone.

We’re looking forward to a great week of conversations in the historic heart of Vienna. 🏛️🌹

EBD Group #PYC #MIDD #Biostatistics #Bioinformatics #DrugDevelopment #Pharma #Biotech

What a horrible person you are

I've bought at 5yr lows and intended to double my money like on WHI

If you have been let down by POLX email amd speak to them rather than subject me and others to abuse

Filtered

Yes, i am currently 200% up but believe new mgmt should aim to get WHI to 4p/5p again

Expecting same at POLX

Polx charts bottomed, block buying, should be a good blue day today

Quite what green boxes were doing posting on a share they dont own after 10.30pm is beyond most normal comprehension

1) Large holders (2 industry linked) make offer

2) continued orders from the other 19 USA states

3) BOD review.options properly ( POLX still has aboit $5mlnn of cash as of Nov)

Turnthecornor

Good afternoon

Yes, GDR has shown what can happen

Is back

03-Nov-2512:05:530.152

2,500,000

0.148

1,000,000

Brilliant news Trench

After the fall from 1.4p the charts are very very oversold

I am watching for a potential purchase

Global politics means energy self sufficiency even more important for UK

Sami

Copy and paste text whole post into a separate word document

Brilliant KingH.

Do you think this is DoseMeRx?

Either way , great that our largest market (USA) is doing this

We know from PYC that we have lots of regulatory help

Biostatistics now compulsory

Project optimus FDA

Etc